112 related articles for article (PubMed ID: 21703986)
1. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy.
Niam M; Linn YC; Fook Chong S; Lim TJ; Chu S; Choong A; Yong HX; Suck G; Chan M; Koh M
Exp Hematol; 2011 Sep; 39(9):897-903.e1. PubMed ID: 21703986
[TBL] [Abstract][Full Text] [Related]
2. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
Linn YC; Yong HX; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M
Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
[TBL] [Abstract][Full Text] [Related]
4. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
6. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.
Introna M; Franceschetti M; Ciocca A; Borleri G; Conti E; Golay J; Rambaldi A
Bone Marrow Transplant; 2006 Nov; 38(9):621-7. PubMed ID: 16980990
[TBL] [Abstract][Full Text] [Related]
7. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
8. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies.
Linn YC; Niam M; Chu S; Choong A; Yong HX; Heng KK; Hwang W; Loh Y; Goh YT; Suck G; Chan M; Koh M
Bone Marrow Transplant; 2012 Jul; 47(7):957-66. PubMed ID: 21986635
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
11. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.
Introna M; Pievani A; Borleri G; Capelli C; Algarotti A; Micò C; Grassi A; Oldani E; Golay J; Rambaldi A
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1603-7. PubMed ID: 20685246
[TBL] [Abstract][Full Text] [Related]
13. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells.
Li Y; Schmidt-Wolf IG; Wu YF; Huang SL; Wei J; Fang J; Huang K; Zhou DH
Anticancer Res; 2010 Sep; 30(9):3493-9. PubMed ID: 20944128
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
16. [Nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study].
Liu L; Liu Q; Hao MW; Chen RA; Zhang JL; Wang LH; He H; Jiang SS; Liang YM
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1102-5. PubMed ID: 16029566
[TBL] [Abstract][Full Text] [Related]
17. Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells.
Zanon C; Stocchero M; Albiero E; Castegnaro S; Chieregato K; Madeo D; Rodeghiero F; Astori G
Cytometry B Clin Cytom; 2014 Jul; 86(4):257-62. PubMed ID: 24002818
[TBL] [Abstract][Full Text] [Related]
18. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
[TBL] [Abstract][Full Text] [Related]
19. Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization.
Olavarria E; Parker S; Craddock C; Philpott N; Tiniakou M; Chase A; Kanfer E; Apperley JF; Goldman JM
Haematologica; 2000 Jun; 85(6):647-52. PubMed ID: 10870123
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]